Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-03-10 Transaction in Own Shar…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document title is "Déclaration des transactions sur actions propres" (Declaration of transactions on own shares). The content details specific transactions (volume, price, date) involving Sanofi buying back its own shares between March 3rd and March 7th, 2025. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS).
2025-03-10 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares
2025-03-10 English
6-K
Regulatory Filings
2025-03-10 English
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Regulatory Filings Classification · 96% confidence The document is explicitly titled and formatted as a "Press Release" announcing positive pivotal study data for Dupixent in bullous pemphigoid, presented at the AAD Annual Meeting. It details clinical trial results (primary and secondary endpoints, safety data) and mentions regulatory submissions (FDA priority review acceptance, EU review). This content structure—announcing key clinical/regulatory milestones via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K/IR), a transcript (CT), or a formal regulatory filing like a proxy statement, the most appropriate classification for a major, time-sensitive announcement of clinical trial results and regulatory progress is Earnings Release (ER), as these often accompany or precede quarterly financial reporting periods, or the general Regulatory Filings (RNS) if ER is too specific. Given the focus on clinical trial results and regulatory updates, ER is often used for such major news, but since it's not explicitly an earnings report, and it's a general announcement of data presentation and regulatory status, it fits well under the broad category of a significant corporate announcement. However, looking at the definitions, 'ER' is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical/regulatory highlight, not a financial highlight. Therefore, the best fit among the provided options for a significant, non-financial, non-meeting related corporate announcement that doesn't fit elsewhere is the fallback category, Regulatory Filings (RNS), as it covers general regulatory announcements and miscellaneous filings.
2025-03-08 English
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Regulatory Filings Classification · 96% confidence The document is explicitly titled and formatted as a "Press Release" announcing positive pivotal study data for Dupixent in bullous pemphigoid, presented at the AAD Annual Meeting. It details clinical trial results (primary and secondary endpoints, safety data) and mentions regulatory submissions (FDA priority review acceptance, EU review). This content structure—announcing key clinical/regulatory milestones via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K/IR), a transcript (CT), or a formal regulatory filing like a proxy statement, the most appropriate classification for a major, time-sensitive announcement of clinical trial results and regulatory progress is Earnings Release (ER), as these often accompany or precede quarterly financial reporting periods, or the general Regulatory Filings (RNS) if ER is too specific. Given the focus on clinical trial results and regulatory updates, ER is often used for such major news, but since it's not explicitly an earnings report, and it's a general announcement of data presentation and regulatory status, it fits well under the broad category of a significant corporate announcement. However, looking at the definitions, 'ER' is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical/regulatory highlight, not a financial highlight. Therefore, the best fit among the provided options for a significant, non-financial, non-meeting related corporate announcement that doesn't fit elsewhere is the fallback category, Regulatory Filings (RNS), as it covers general regulatory announcements and miscellaneous filings.
2025-03-08 English
6-K
Regulatory Filings
2025-03-06 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.